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Background 
– Concerns about ability of current systems to provide timely access to 
medicines
– Potential policy approaches 
– Special funds for medicines that do not meet cost-effectiveness criteria
– Personal importation 
– Conditional registration and reimbursement mechanisms
– Unclear risk-benefit balance 
– Wider range of treatment options and earlier access to medicines 
– Increase uncertainty surrounding safety, efficacy and cost-effectiveness
– Stakeholder engagement to determine appropriate risk-benefit balance
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Research Questions 
– What are the beliefs and values of consumers regarding the 
approval and funding of new medicines?
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Methods: Survey  
– 59-item telephone survey conducted in August 2018 
– Explore what Australians think about funding cancer medicines 
– 1039 participants, largely representative of the broader 
population
– Fixed choice survey items 
– Responses tallied, proportions calculated
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Methods: Interviews and Focus Groups  
– 13 semi-structured interviews with patients and patient 
advocates 
– Between 30 and 60 minutes 
– 2 focus groups with patients 
– 1.5 hours
– Purposive, convenience and snowball sampling 
– Audio recorded, transcribed verbatim and analysed 
thematically
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Findings: Survey 
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Findings: Survey Cont’d  
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Findings: Interviews and Focus Groups 
– Expressed need for faster access to promising medications for 
some patients 
If  you wait for all that process, you’ve got a whole lot of  people 
dying unnecessarily. 
When my dad was diagnosed with prostate cancer, I discovered a 
drug in America that was in clinical trials, but we couldn’t get access 
to the drug … It’s kind of  like why do people in America have access 
to this, just because we live in Australia we don’t?  
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Findings: Interviews and Focus Groups Cont’d  
– Cognisant of potential risks of accelerated access
– Safety and efficacy 
So there’s a trade-off  between time and the cost involved in [drug 
evaluation], and the safety of  making sure that we don’t do people 
damage. 
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Findings: Interviews and Focus Groups Cont’d  
– Budget impact, sustainability of healthcare systems and 
opportunity costs 
It has to be sustainable, financially sustainable. There has to be a 
budget.
It’s like where do you take the money from, is that okay to take it 
from, you know, education?  Not necessarily.  They could be the 
researchers that invent the cure for cancer.  It’s hard.
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Findings: Interviews and Focus Groups Cont’d  
– Overall happy with existing systems and didn’t see need for 
wholesale changes 
The system we’ve got is good…. I think the community understands 
that there’s a limit to what can be on PBS. 
In general, the community are comfortable with the PBS. 
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Policy Implications 
– Nuanced consumer perspectives 
– How the question is asked determines information received 
– Need carefully designed tools to elicit consumer perspectives 
for these to be useful to policy makers 
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Questions
